Skip to main content

Advertisement

Table 3 Treatment-emergent adverse events

From: Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study

Event Weeks 1–8, n (%) Weeks 9–52, n (%) Weeks 1–52, n (%)
Nausea 29 (28.7) 0 (0.0) 29 (28.7)
Dizziness 27 (26.7) 5 (5.0) 31 (30.7)
Somnolence 22 (21.8) 1 (1.0) 23 (22.8)
Constipation 20 (19.8) 5 (5.0) 23 (22.8)
Dry mouth 16 (15.8) 4 (4.0) 18 (17.8)
Insomnia 15 (14.9) 8 (7.9) 22 (21.8)
Headache 11 (10.9) 6 (5.9) 16 (15.8)
Increased sweating 11 (10.9) 4 (4.0) 15 (14.9)
Diarrhea 11 (10.9) 6 (5.9) 17 (16.8)
Tremor 7 (6.9) 2 (2.0) 9 (8.9)
Anxiety NEC 7 (6.9) 3 (3.0) 10 (9.9)
Fatigue 7 (6.9) 4 (4.0) 9 (8.9)
Decreased appetite 7 (6.9) 1 (1.0) 7 (6.9)
Vomiting 7 (6.9) 3 (3.0) 10 (9.9)
Anorexia 6 (5.9) 3 (3.0) 8 (7.9)
Back pain 5 (5.0) 2 (2.0) 6 (5.9)
Abdominal pain upper 4 (4.0) 2 (2.0) 6 (5.9)
  1. † Events with an occurrence > 5% in Weeks 1–52.